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8.1  Historical Perspective 
 The potential of radionuclides as tracers for the investigation of the circulation was 
realised many years ago but early experiments were hampered by primitive equip-
ment. Blumgart and colleagues reported the fi rst use of a radionuclide tracer in man 
in 1927. They used a cloud chamber to measure the transit time of intravenous 
radium C from one arm to the other and they noted much longer circulation times in 
patients with heart failure. In the late 1940s Prinzmetal and colleagues established 
the use of precordial time-activity curves following intravenous injection of a bolus 
of radionuclide. They used sodium-24 and a Geiger-Müller tube, but the technique 
was developed using iodine-131 and a more reliable scintillation counter by Shipley 
and colleagues, and was used by Huff and colleagues in conjunction with the 
Hamilton equation to measure cardiac output. 
 The fi rst cardiac images were produced using a rectilinear scanner but further 
advances were made with the development of more suitable radioactive tracers and 
more sophisticated imaging equipment. In 1957 Anger’s invention of the gamma 
camera opened the door for rapid development, initially with blood pool imaging, 
progressing to myocardial imaging, cardiac PET, and the multi-faceted discipline 
that is now an essential part of clinical cardiology (Table  8.1 ).
 Along the way, UK-based researchers and clinicians have made signifi cant con-
tributions. Groups based in Aberdeen (cardiac PET), Northwick Park Hospital 
(technetium-based perfusion tracers), St Bartholomew’s Hospital (fi rst pass blood 
pool imaging), Hammersmith Hospital (cardiac PET), University College Hospitals 
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(ECG-gated SPECT, rubidium-82, solid state cameras), Manchester Royal Infi rmary 
(rubidium-82) and Royal Brompton & Harefi eld Hospitals (pharmacological stress, 
heart failure, cost-effectiveness) have all infl uenced the fi eld internationally. The 
BNMS can be proud of the achievements of its members. 
8.2  Radionuclide Ventriculography 
 In the late 1970s and early 1980s radionuclide ventriculography (RNV) was the 
main nuclear cardiology technique and it was used increasingly as an accurate and 
reproducible method of assessing left ventricular (LV) function. Although equilib-
rium imaging was most commonly used, fi rst pass imaging had particular advan-
tages for assessing right ventricular function and intra-cardiac shunting, as 
successfully used by the paediatric cardiologists at Guy’s Hospital [ 1 ]. Parametric 
imaging provided simple methods of visualising regional function from the phase 
and amplitude images [ 2 ]. The Institute of Nuclear Medicine under the guidance of 
Peter Ell at the Middlesex Hospital demonstrated the value of such functional 
imaging in clinical practice (Fig.  8.1 ), and the phase image in particular continues 
to be of interest in assessing ventricular dysynchrony before resynchronisation 
pacing in patients with heart failure. This group also pioneered gated blood pool 
tomography [ 3 ] but with only two 100 ms frames per cardiac cycle it was not until 
image acquisition and processing techniques improved that it became a realistic 
technique as used today.
 The simplicity and reproducibility of RNV meant that it was the technique of 
choice for serial assessments of LV function in patients having cardiotoxic che-
motherapy or after heart transplantation but the increasing availability of echo-
cardiography and its lack of ionising radiation led to it effectively replacing 
RNV. The availability of accurate methods of assessing LV function from gated 
myocardial SPECT led to a further decline, although RNV remains a valuable 
technique when echocardiography or magnetic resonance imaging (MRI) are not 
possible. 
 Table 8.1  Developing techniques in nuclear cardiology 
 Decade  Clinical developments 
 ≤1960s  Experimental 
 1970s  Blood pool imaging 
 1980s  Thallium, diagnosis, cardiac cameras, pharmacological stress 
 1990s  Technetium perfusion tracers, prognosis, attenuation correction, reconstruction techniques 
 2000s  Hibernation, cost-effectiveness, solid state cameras, SPECT-CT, competing techniques 
 2010s  Patient outcome, new tracers, cardiac PET-CT, infl ammation and infection imaging 
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8.3  Myocardial Perfusion Scintigraphy 
 As RNV was becoming less popular, so the combined assessment of myocardial 
viability and perfusion using thallium-201 and technetium-99m MIBI and tetro-
fosmin developed. Myocardial perfusion scintigraphy (MPS) is now the dominant 
nuclear cardiology technique that should be available to all cardiac services 
although appropriate expertise is not always available and there are still UK sites 
that rely on other techniques for coronary functional imaging. Planar MPS was 
effectively replaced by SPECT in the 1980s and it has developed from a diagnos-
tic technique to a method of assessing prognosis and hence guiding clinical man-
agement and improving clinical outcome in patients with coronary artery disease 
(CAD). MPS SPECT has also become an alternative to FDG PET in assessing 
patients with ischaemic LV dysfunction and possible hibernating myocardium 
(Fig.  8.2 ) [ 4 ].
 When the technetium-99m labelled perfusion tracers, MIBI and tetrofosmin were 
introduced in the 1990s many sites switched entirely to these despite some of their 
disadvantages [ 5 ]. Apart from commercial marketing, one driver for the change was 
the lower radiation burden of the technetium tracers. However, several recalculations 
 Fig. 8.1  The phase image and LV phase histograms from equilibrium radionuclide ventriculogra-
phy acquired at rest and during maximal dynamic exercise in a patient without coronary disease 
( left ) and one with signifi cant left anterior descending disease ( right ). Mean phase ( φ Mn ) increases 
with heart rate ( P ) but the standard deviation of phase ( φ SD ) broadens in the patient with LAD 
disease indicating delayed contraction in the relevant area. The standard deviation of the phase 
histogram is a sensitive method of detecting inducible ischaemia 
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 Fig. 8.2  Myocardial perfusion scintigraphy in an patient with ischaemic heart disease and heart 
failure. The antero-apical region ( 1 ) is almost fully viable but has inducible hypoperfusion. ECG- 
gating showed it also to be akinetic without thickening and hence hibernating. There is also trans-
mural infarction of the basal inferior wall ( 2 ) extending as partial thickness scarring of the 
infero-lateral region ( 3 ). LVEF was 30 % but improved to 48 % after revascularisation 
have almost equalised the effective doses at 6, 7 and 8 mSv for 1000 MBq of tetro-
fosmin, MIBI and 80 MBq of thallium respectively [ 6 ]. With this new information 
and the superior uptake characteristics for the quantifi cation of perfusion in absolute 




8.4  Pharmacological stress 
 One of the strengths of MPS is that it is not necessary for the patient to exercise 
maximally and pharmacological stress of myocardial perfusion became particu-
larly prevalent in the UK in the 1980s and beyond, such that it is now used in the 
majority of studies instead of dynamic exercise. The coronary vasodilator dipyri-
damole was initially used following validation work by Gould in dogs and it is still 
the commonest pharmacological stressor in countries such as France, primarily 
because it is cheap. The Royal Brompton group was among the fi rst to combine it 
with dynamic exercise in order to improve image quality and reduce side effects 
[ 7 ]. They later extended this to adenosine stress [ 8 ], which effectively replaced 
dipyridamole in the UK because of its shorter half-life and hence safety and prac-
ticality. They were also the fi rst group in Europe to use the more specifi c A2a 
adenosine receptor agonist, regadenoson [ 9 ], which extended the options for stress-
ing patients with obstructive airways disease and potentially also those with con-
ducting tissue disease. 
8.5  NICE and the UK Societies 
 As the NICE programme of clinical guidelines and technology appraisals grew in 
the 1990s it was apparent that the focus of healthcare providers was moving from 
evidence of effectiveness to cost-effectiveness to clinical outcomes. At this stage 
there were only computer-based estimates of cost effectiveness with no supporting 
clinical studies. However, in 1999 clinical cost-effectiveness studies from the UK 
[ 10 ] and USA [ 11 ] provided strong support for MPS at a time when there was no 
similar evidence to support alternatives. The data were considered by NICE and 
formed part of the evidence for the fi rst technology appraisal of an imaging tech-
nique in cardiology [ 12 ]. More recently, the Cambridge group led what is still the 
only prospective randomised study of non-invasive imaging compared with invasive 
angiography and confi rmed the cost-effectiveness of MPS compared with echocar-
diography and MRI [ 13 ]. 
 In assisting the technology appraisal of MPS, the BNMS, BNCS and other pro-
fessional bodies collaborated to review the evidence for MPS in clinical practice 
and the resulting publication became the most quoted EJNM publication in 2008 
[ 14 ]. Since then, an alphabet cocktail of studies (BARI, COURAGE, DEFER, 
ERASE, FAME, GRACE, INSPIRE, etc.) has shown, among other things, that 
ischaemia- guided intervention in patients with CAD leads to better clinical out-
comes. It should now be unusual for patients with stable disease to undergo revas-
cularisation procedures without some form of functional assessment. The challenge 
for the future will be to show the advantages of doing this by nuclear cardiology in 
preference to alternative techniques that in some centres have replaced nuclear car-
diology because of more ready access to expertise and equipment. 
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8.6  The Future 
 Whether nuclear cardiology will move towards PET from SPECT is unclear. FDG 
PET is already very valuable for the assessment of myocardial infl ammation and 
infection, such as in sarcoidosis and infected devices (Fig.  8.3 ).
 For perfusion imaging the future is less clear. UK groups have been at the fore-
front of using rubidium-82 PET, the only perfusion technique that is feasible with-
out an on-site cyclotron, but PET may not gain wide acceptance until more 
cost-effective techniques become available, possibly such as fl urpiridaz, a fl uorine-
 18 labelled perfusion tracer currently in phase 3 trials. In addition, the availability 
of high resolution and sensitive solid state cameras with the ability to quantify per-
fusion may challenge PET (Fig.  8.4 ) [ 15 ,  16 ].
 There is the prospect of moving nuclear cardiology into the world of electro-
physiology interventions, such as ablation of atrial fi brillation and ventricular 
arrhythmias. Pilot studies between University College and Royal Brompton 
Hospitals and have shown that mIBG combined with a solid state camera can local-
ise ganglionated plexi of the sympathetic nervous system that are related to the 
control of arrhythmia and are potential targets for intervention (Fig.  8.5 ).
 Reports of the demise of nuclear cardiology have therefore been exaggerated. Its 
future seems assured provided that we continue our proud history within the BNMS 
of contributing to research, education and clinical application in the fi eld. 
 Fig. 8.3  FDG PET in the coronal plane in a patient with cardiac sarcoidosis before ( left ) and 10 
months after steroid therapy ( right ). The images are acquired in the fasting state to suppress normal 
myocardial glucose metabolism. There is intense abnormal activity in the heart and hilar regions 




 Fig. 8.4  Myocardial perfusion scintigraphy in an patient with known coronary disease, acquired 
using a solid state gamma camera in 4 min ( left ) and a conventional camera in 12 min ( right ). In 
each case stress tomograms are on the left and rest on the right. Both studies show an inducible 
perfusion abnormality of the basal inferior wall ( 1 ) but the superior spatial and contrast resolution 
of the solid state camera is obvious 
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 Fig. 8.5  Segmented CT scan with the sites of ganglionated plexi (GPs) superimposed ( green 
ovals ) imaged using iodine-123 mIBG and a solid state gamma camera. The fused images can be 
imported into the electrophysiology laboratory system to aid localisation of the GPs and ablation 
(Courtesy Dr Sabine Ernst, Royal Brompton Hospital).  LA left atrium,  LV left ventricle,  RA right 
atrium,  SVC superior vena cava 
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